Subscribe

a website banner telling users to subscribe to it's newsletter

  • Home
  • Breaking News
  • FDA Recalls Eye Ointments Sold at Walmart and CVS Over Infection Risk
FDA Recalls Eye Ointments Sold at Walmart and CVS Over Infection Risk

FDA Recalls Eye Ointments Sold at Walmart and CVS Over Infection Risk

February 28, 2024

Eye ointment products manufactured in India and sold in the United States at major retailers like Walmart and CVS are being recalled due to a danger of infection. Brassica Pharma Pvt. Ltd., based in Maharashtra, India, announced the recall of various eye lubricant products labeled Equate, CVS Health, and AACE. The recalled products have expiration dates ranging from February 2024 to September 2025.

Potential Risks and Safety Measures

"For those patients who use these products, there is a potential risk of eye infections or related harm. These products are intended to be sterile," stated Brassica Pharma in a statement posted by the U.S. Food and Drug Administration. The company highlighted the heightened risk posed by ophthalmic drug products due to bypassing some of the body's natural defenses.

The recall follows a previous incident in 2023 involving tainted eye drops, emphasizing the importance of stringent quality control measures in pharmaceutical manufacturing. Click to see the list recalled eye drops in 2023.

Brassica Pharma noted that no reports of adverse events tied to the ointments have been received thus far. However, consumers, distributors, and retailers are urged to discontinue the distribution and use of the affected products.

"These products were distributed nationwide to wholesalers, retailers, and via the product distributor, Walmart, CVS, and AACE Pharmaceuticals Inc.," added Brassica Pharma. Consumers are advised to stop using the recalled eye ointment and may return any of the affected products to the place of purchase.

Ensuring Safety Amidst FDA Recalls

To ensure your safety amidst FDA recalls of eye drops, it's crucial to stay informed. Our news article provides comprehensive information on how to protect yourself from the risks associated with recalled eye drops. 

*Stay in the loop and make sure not to miss real-time breaking news about ophthalmology. Join our community by subscribing to OBN newsletter now, and get weekly updates.

Topics
Recall FDA Eye Drop

RELATED POSTS

Benefits Of Combination Drops On Glaucoma Management
Benefits Of Combination Drops On Glaucoma Management
4159 read
FDA Approves Apellis' Syfovre as First and Only Treatment for Geographic Atrophy
FDA Approves Apellis' Syfovre as First and Only Treatment for Geographic Atrophy
6019 read
Roche's Vabysmo Improves Vision, Retinal Fluid In Retinal Disorder, New Study Finds
Roche's Vabysmo Improves Vision, Retinal Fluid In Retinal Disorder, New Study Finds
3600 read
UVA Researchers Discover Potential New Way to Prevent Vision Loss
UVA Researchers Discover Potential New Way to Prevent Vision Loss
1115 read
DORC Receives FDA Clearance for Eva Nexus System
DORC Receives FDA Clearance for Eva Nexus System
2456 read
Researchers Develop Glaucoma Cell Replacement Therapy to Reverse Vision Loss
Researchers Develop Glaucoma Cell Replacement Therapy to Reverse Vision Loss
2814 read
Vyjuvek Eye Drop Restores Vision in Teen with Rare Genetic Condition
Vyjuvek Eye Drop Restores Vision in Teen with Rare Genetic Condition
2728 read
Novel AI Detects Retinopathy of Prematurity with 100% Accuracy
Novel AI Detects Retinopathy of Prematurity with 100% Accuracy
1427 read
FDA Approves Regeneron’s EYLEA® as the First Pharmacologic Treatment for Preterm Infants with ROP
FDA Approves Regeneron’s EYLEA® as the First Pharmacologic Treatment for Preterm Infants with ROP
3885 read
FDA Warns 8 Companies for Marketing Unapproved Eye Products
FDA Warns 8 Companies for Marketing Unapproved Eye Products
5373 read